Delivery Order SPE2DB20D2014-SPE2DB25FC54C
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,669.96 by the Defense Logistics Agency on July 28, 2025, for the supply of Trulicity 1.5 mg/0.5 ml pens. The contract utilizes firm fixed pricing with no set-aside designation and is scheduled for completion by July 29, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $1,302.84 for Trulicity 1.5 mg/0.5 ml pens by the Defense Logistics Agency's Medical Supply Chain on July 24, 2025. This firm fixed-price contract is not set-aside and represents a single delivery of the diabetes medication to support military healthcare operations. The award is structured as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,204.98 on July 28, 2025, for the supply of Trulicity 1.5 mg/0.5 mL pens (0.5 mL units), a diabetes medication. This competitive award employs firm fixed pricing and is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract specifies a...
- The Defense Logistics Agency awarded a $4,281.86 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pens on July 21, 2025, with completion expected by July 22, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1 billion through December 2026. The pharmaceutical product will be delivered to...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a competitive delivery order award from the Defense Logistics Agency valued at $1,174.94 for Trulicity 0.75 mg/0.5 ml pen medication. The contract carries a firm fixed price structure with an ultimate completion date of July 25, 2025, and was awarded on July 24, 2025. This delivery order represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,656.36 fixed-price delivery order is for the supply of the pharmaceutical product TRULICITY 1.5 MG/0.5 ML PEN 0.5ML. The contract has a completion date of February 9, 2023. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,307.68 firm fixed price delivery order is for the supply of Trulicity 1.5 mg/0.5 ml pens, a medication used to manage diabetes. The contract has an ultimate completion date of October 31, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order with a ceiling value of $4,762.34. The contract, awarded by the Defense Logistics Agency (DLA), is for the supply of TRULICITY 1.5 MG/0.5 ML PEN 0.5ML, a diabetes management medication. The contract has an ultimate completion date of May 8, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,467.38 Firm Fixed Price contract is for the delivery of Trulicity 3 mg/0.5 ml pens, a pharmaceutical product for diabetes management. This is a Delivery Order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,603.60 firm fixed-price delivery order is for the supply of Trulicity 0.75 mg/0.5 ml pens, a medication used to manage diabetes. The contract has an ultimate completion date of December 16, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC54CDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $2,252.25 by the Defense Logistics Agency on July 23, 2025. The contract calls for delivery of Trulicity 3 mg/0.5 ml pens (0.5ml units), a diabetes medication commonly used within military and federal healthcare systems. This is a non-set-aside award issued under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. This delivery order represents a routine transaction within AmerisourceBergen's substantial federal contracting portfolio with the Defense Logistics Agency's Medical Supply Chain. The contract is structured as a child award under the larger SPE2DX prime vendor agreement, which encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The company's competitive position in federal pharmaceutical procurement is demonstrated through its consistent receipt of non-set-aside awards and its designation as a preferred supplier for military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/23/25 |